141 related articles for article (PubMed ID: 38334950)
1. Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma.
Griesinger AM; Calzadilla AJ; Grimaldo E; Donson AM; Amani V; Pierce AM; Steiner J; Kargar S; Serkova NJ; Bertrand KC; Wright KD; Vibhakar R; Hankinson T; Handler M; Lindsay HB; Foreman NK; Dorris K
Clin Cancer Res; 2024 Apr; 30(8):1544-1554. PubMed ID: 38334950
[TBL] [Abstract][Full Text] [Related]
2. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.
Pierce AM; Witt DA; Donson AM; Gilani A; Sanford B; Sill M; Van Court B; Oweida A; Prince EW; Steiner J; Danis E; Dorris K; Hankinson T; Handler MH; Jones KL; Karam SD; Serkova NJ; Vibhakar R; Foreman NK; Griesinger AM
Neuro Oncol; 2019 Dec; 21(12):1540-1551. PubMed ID: 31276586
[TBL] [Abstract][Full Text] [Related]
3. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
Donson AM; Bertrand KC; Riemondy KA; Gao D; Zhuang Y; Sanford B; Norris GA; Chapman RJ; Fu R; Willard N; Griesinger AM; Ribeiro de Sousa G; Amani V; Grimaldo E; Hankinson TC; Booker F; Sill M; Grundy RG; Pajtler KW; Ellison DW; Foreman NK; Ritzmann TA
Neuro Oncol; 2023 Oct; 25(10):1854-1867. PubMed ID: 37246777
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.
Amani V; Donson AM; Lummus SC; Prince EW; Griesinger AM; Witt DA; Hankinson TC; Handler MH; Dorris K; Vibhakar R; Foreman NK; Hoffman LM
J Neuropathol Exp Neurol; 2017 Jul; 76(7):595-604. PubMed ID: 28863455
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
8. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
9. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
[TBL] [Abstract][Full Text] [Related]
10. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification.
Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M
J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871
[TBL] [Abstract][Full Text] [Related]
11. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.
Merchant TE; Bendel AE; Sabin ND; Burger PC; Shaw DW; Chang E; Wu S; Zhou T; Eisenstat DD; Foreman NK; Fuller CE; Anderson ET; Hukin J; Lau CC; Pollack IF; Laningham FH; Lustig RH; Armstrong FD; Handler MH; Williams-Hughes C; Kessel S; Kocak M; Ellison DW; Ramaswamy V
J Clin Oncol; 2019 Apr; 37(12):974-983. PubMed ID: 30811284
[TBL] [Abstract][Full Text] [Related]
12. Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort.
Jünger ST; Mynarek M; Wohlers I; Dörner E; Mühlen AZ; Velez-Char N; von Hoff K; Rutkowski S; Warmuth-Metz M; Kortmann RD; Timmermann B; Rahmann S; Klein-Hitpass L; von Bueren AO; Pietsch T
Acta Neuropathol Commun; 2019 Nov; 7(1):181. PubMed ID: 31727173
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.
Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG
Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DT; Luu B; Cavalli FM; Aldape K; Remke M; Mynarek M; Rutkowski S; Gururangan S; McLendon RE; Lipp ES; Dunham C; Hukin J; Eisenstat DD; Fulton D; van Landeghem FK; Santi M; van Veelen ML; Van Meir EG; Osuka S; Fan X; Muraszko KM; Tirapelli DP; Oba-Shinjo SM; Marie SK; Carlotti CG; Lee JY; Rao AA; Giannini C; Faria CC; Nunes S; Mora J; Hamilton RL; Hauser P; Jabado N; Petrecca K; Jung S; Massimi L; Zollo M; Cinalli G; Bognár L; Klekner A; Hortobágyi T; Leary S; Ermoian RP; Olson JM; Leonard JR; Gardner C; Grajkowska WA; Chambless LB; Cain J; Eberhart CG; Ahsan S; Massimino M; Giangaspero F; Buttarelli FR; Packer RJ; Emery L; Yong WH; Soto H; Liau LM; Everson R; Grossbach A; Shalaby T; Grotzer M; Karajannis MA; Zagzag D; Wheeler H; von Hoff K; Alonso MM; Tuñon T; Schüller U; Zitterbart K; Sterba J; Chan JA; Guzman M; Elbabaa SK; Colman H; Dhall G; Fisher PG; Fouladi M; Gajjar A; Goldman S; Hwang E; Kool M; Ladha H; Vera-Bolanos E; Wani K; Lieberman F; Mikkelsen T; Omuro AM; Pollack IF; Prados M; Robins HI; Soffietti R; Wu J; Metellus P; Tabori U; Bartels U; Bouffet E; Hawkins CE; Rutka JT; Dirks P; Pfister SM; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Ellison DW; Taylor MD
J Clin Oncol; 2016 Jul; 34(21):2468-77. PubMed ID: 27269943
[TBL] [Abstract][Full Text] [Related]
16. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
[TBL] [Abstract][Full Text] [Related]
17. Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost.
Zapotocky M; Beera K; Adamski J; Laperierre N; Guger S; Janzen L; Lassaletta A; Figueiredo Nobre L; Bartels U; Tabori U; Hawkins C; Urbach S; Tsang DS; Dirks PB; Taylor MD; Bouffet E; Mabbott DJ; Ramaswamy V
Cancer; 2019 Jun; 125(11):1867-1876. PubMed ID: 30768777
[TBL] [Abstract][Full Text] [Related]
18. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.
Baroni LV; Sundaresan L; Heled A; Coltin H; Pajtler KW; Lin T; Merchant TE; McLendon R; Faria C; Buntine M; White CL; Pfister SM; Gilbert MR; Armstrong TS; Bouffet E; Kumar S; Taylor MD; Aldape KD; Ellison DW; Gottardo NG; Kool M; Korshunov A; Hansford JR; Ramaswamy V
Neuro Oncol; 2021 Aug; 23(8):1360-1370. PubMed ID: 33580238
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
20. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
